TENEOBIO
TeneoBio is a biotechnology company that specializes in the development of human heavy chain antibodies. It has several products in pre-clinical and clinical development for the treatment of multiple myeloma, prostate cancer, and immune disorders. TeneoBio’s antibody discovery engine is based on UniRat™, a proprietary heavy chain only, human immunoglobulin transgenic rat.
TENEOBIO
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2009-01-01
Address:
Newark, California, United States
Country:
United States
Website Url:
http://www.teneobio.com
Total Employee:
1+
Status:
Active
Contact:
650-899-8200
Technology used in webpage:
Domain Not Resolving SPF Amazon Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Amazon Route 53 AWS Global Accelerator MediaElement.js Amazon Oregon Region
Similar Organizations
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Solvanix
Solvanix is a biotechnology company that improves stability and reducing the aggregation of fully human antibodies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Lightspeed Venture Partners
Lightspeed Venture Partners investment in Venture Round - TeneoBio
Sutter Hill Ventures
Sutter Hill Ventures investment in Venture Round - TeneoBio
Official Site Inspections
http://www.teneobio.com Semrush global rank: 8.49 M Semrush visits lastest month: 523
- Host name: a4ec4c6ea1c92e2e6.awsglobalaccelerator.com
- IP address: 3.33.152.147
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "TeneoBio"
TeneoBio - Crunchbase Company Profile & Funding
TeneoBio is a biotechnology company that specializes in the development of human heavy chain antibodies. It has several products in pre-clinical and …See details»
Teneobio - Amgen
Amgen’s Acquisition of Teneobio is Now Complete. Learn More.See details»
Amgen To Acquire Privately Held Teneobio For $900 Million In …
Jul 27, 2021 THOUSAND OAKS, Calif. and NEWARK, Calif., July 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen …See details»
Amgen Successfully Completes Acquisition Of Teneobio, Inc.
THOUSAND OAKS, Calif., Oct. 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of …See details»
Amgen Successfully Completes Acquisition Of Teneobio, Inc. - PR …
Effective as of Oct. 19, 2021, Amgen has acquired all outstanding equity of Teneobio in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments, to …See details»
Teneobio, Inc. Company Profile | Newark, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Teneobio, Inc. of Newark, CA. Get the latest business insights from Dun & Bradstreet.See details»
Press Release Distribution and Management - GlobeNewswire
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic …See details»
TeneoBio 2025 Company Profile: Valuation, Investors ... - PitchBook
TeneoBio has raised $13.5M. Who are TeneoBio’s investors? Lightspeed Venture Partners and Tesaro have invested in TeneoBio. Who are TeneoBio’s competitors? Linnaeus Therapeutics …See details»
TeneoBio Company Profile - Office Locations, Competitors ... - Craft
TeneoBio is a biotechnology company developing biologics such as human heavy chain antibodies (UniAbs) as therapeutics against cancer, autoimmunity, and infectious diseases. It …See details»
$2.5B Teneobio Deal Complements Amgen’s Core and …
Jul 28, 2021 Michael Vi / Shutterstock. Amgen is snapping up privately-held TeneoBio and its class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.. Through the acquisition, which includes a …See details»
Amgen finalizes Teneobio acquisition - Drug Discovery …
Oct 19, 2021 Before the acquisition, Teneobio distributed some assets to its equity holders related to three affiliates dubbed “TeneoTwo,” “TeneoFour” and “TeneoTen.” Among the included assets were TNB-486, anti-CD38 antibodies …See details»
Gilead-partnered Teneobio and its next-gen cancer work snapped …
Jul 28, 2021 “The Teneobio team is enthusiastic about joining forces with Amgen, a pioneer of biotherapeutics. Amgen's R&D resources and its extensive clinical experience in immuno …See details»
Teneobio falls short of Amgen’s expectations - ApexOnco
Oct 31, 2023 Amgen had bought Teneobio, a subsidiary of a private business focusing on heavy chain-only antibodies, for $993m up front, and AMG 340, a T-cell engager against PSMA that …See details»
Teneobio Acquisition Adds Talent and New Types of Antibodies to …
Jan 14, 2022 Teneobio has engineered a T cell engager that binds with a very low affinity to the CD3 receptor on T cells. Both high- and low-affinity T cell binders are needed in cancer …See details»
Kite Licenses Antibodies and Establishes Collaboration With …
Apr 2, 2020 SANTA MONICA, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a …See details»
Amgen stops cancer trial, taking $650M BiTE out of earnings
Oct 31, 2023 Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings. The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in …See details»
Etentamig - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 10, 2025 Etentamig: a BCMA inhibitors, CD3 stimulants Drug, Initially developed by TeneoBio, Inc., Now, its global highest R&D status is Phase 3, Mechanism: BCMA inhibitors(B …See details»
Potential Myeloma Treatment, TNB-383B, Makes Progress in New …
Feb 20, 2019 Teneobio has already filed an investigational new drug application with the U.S. Food and Drug Administration in January 2019 to begin clinical testing of TNB-383B as …See details»
Multi-specific therapeutic antibodies - FreeMind Group
Page 3 Teneobio Overview Proprietary transgenic rats for human antibody discovery UniRat and Omniflic High throughput sequence-based human antibody discovery engine Next-gen …See details»
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody …
3 Teneobio, Inc, Newark, California, USA [email protected]. PMID: 34088740 PMCID: PMC8183203 DOI: 10.1136/jitc-2021-002488 Abstract Background: Therapeutic options …See details»